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Abstract: Tumor cells have unique metabolic demands, and their metabolic processes require large amounts 
of glutamine. Glutamine is closely related to the growth and proliferation of tumor cells, and it can regulate 
cell survival, metabolism, signal transduction, autophagy, etc. Alanine-serine-cysteine transporter 2 (ASCT2) 
is Na+-dependent transmembrane transporter in charge of transporting glutamine and some macromolecular 
neutral amino acids. ASCT2 is overexpressed in many kinds of tumor cells, and the high expression of ASCT2 
is positively correlated with the poor prognosis of tumor patients. Recently, the glutamine metabolism and 
transporters have been developed as therapeutic targets for treating various cancers. However, the studies on 
the glutamine transporters in China remain largely unknown. In this paper, we review the recent progress of 
structure, expression and role of ASCT2 in cancer.
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摘  要：肿瘤细胞具有独特的代谢需求，其代谢过程需要消耗大量的谷氨酰胺。谷氨酰胺与肿瘤细胞
的增殖密切相关，它可以调节细胞的存活、代谢、信号转导、自噬等。丙氨酸-丝氨酸-半胱氨酸转运


























家族1（solute carrier family 1, SLC1）、溶质载体
家族6（solute carrier family 6, SLC6）、溶质载
体家族7（solute carrier family 7, SLC7）、溶质
载体家族38（solute carrier family 38, SLC38）。
ASCT2属于溶质载体家族1成员5（solute carrier 

































































































































































图 1  谷氨酰胺分解活化 R a g -
mTORC1信号通路[16-17]
Figure1 Glutaminolysis activates 
mammalian TORC1 (mTORC1) via 
Rag[16-17]
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